Overexpression of PD-L1 is an Independent Predictor for Recurrence in HCC Patients Who Receive Sorafenib Treatment After Surgical Resection.

ABSTRACT:

Objective

The predicting values of programmed cell death protein 1 (PD-1) and programmed death-ligand 1(PD-L1) were unclear in Hepatocellular carcinoma (HCC) patients who receive sorafenib treatment after curative hepatic resection.

Methods

We retrospectively enrolled HCC patients who received adjuvant sorafenib treatment after curative resection (N = 154), and patients had resection alone (N = 312). Immunohistochemistry was used to assess expression of PD-1 on tumor infiltration immune cells and PD-L1 on HCC cells. Cox proportional hazard models were used to explore association between clinicopathological factors and risk of tumor recurrence.

Results

No significant difference was detected in RFS (p = 0.542), or OS (p = 0.542) between the resection and sorafenib group

SUBMITTER: Tan Y 

PROVIDER: S-EPMC8804345 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature